Navigation Links
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Date:3/14/2008

CAMBRIDGE, Mass., March 14 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that enrollment has been completed in a Phase 2 trial of 100 patients that evaluates the safety and efficacy of its lead product, MM-093, in patients suffering from rheumatoid arthritis (RA). MM-093 is a recombinant version of human alpha-fetoprotein (AFP).

The randomized, double-blind, placebo-controlled, Phase 2 study is being conducted at 20 centers throughout the United States. The objective of this study is to examine the safety and efficacy of MM-093 in patients with moderate to severe, active RA despite treatment with stable doses of methotrexate. Each patient receives 60mg of MM-093 per week or placebo for 12 weeks and will then be followed for a period of 4 weeks. In addition to evaluating the safety of MM-093, patients will be assessed for changes in the signs and symptoms of their disease using standard clinical outcome measurements for RA, such as ACR20 and DAS28 scores. Patients who complete the study are eligible to participate in an ongoing Open-Label Extension study, which has enrolled over 35 patients to date.

"We are pleased to have completed enrollment and are thankful for the enthusiasm of the investigators who have worked diligently to enroll patients," said Dr. William Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "We believe MM-093 represents a promising and novel approach to the treatment of a broad range of autoimmune diseases. We look forward to completing the study and communicating the results later this year."

In addition to the ongoing studies in RA, MM-093 is currently being tested in a pilot study for patients with certain types of autoimmune uveitis, an inflammatory disorder of the eye.

Merrimack controls a strong intellectual property estate around MM-093 including 15 issued patents and a number of pending applications, both in the U.S. and internationally, which cover composition
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
2. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
3. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
4. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
11. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, The ... support that prevents ankle sprains by cushioning the ankle ... fits securely around the outside of any shoe type ... comfort while still offering protection against sprains. With customers ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 2015   Leatt Corporation  (OTCQB: LEAT), a global developer, ... forms of sports, including extreme motor sports, and whose ... that the UISP Lega Motociclismo Lombardia, an Italian motocross ... wear a neck brace during its racing competitions.  ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... an international generic pharmaceuticals company, today announced that it ... Administration to market Valacyclovir Hydrochloride Tablets.     ... generic equivalent of Valtrex® by GlaxoSmithKline, had US sales ... December 31, 2010, according to IMS Health.     ...
... 2011 Amgen (Nasdaq: AMGN ) today ... and fifth years of Prolia® (denosumab) treatment, postmenopausal women ... year-over-year increases in lumbar spine and total hip bone ... The overall adverse event profile was similar for the ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 3Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 4Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 5Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 6Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 7Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 8Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 9
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:12/26/2014)... TX (PRWEB) December 26, 2014 The US ... in this report. In 2013, GlobalData’s forecast estimates that sales ... largest CRC market due to the high incidence of the ... with the 5EU, Japan, and China. Increased sales of CRC ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... delivers immediate cost savings for http://www.lle-inc.com/link.html [24-hour telephone ... or seeking multilingual solutions. , ... ... LLE® http://www.lle-inc.com/index.html [(Language Learning Enterprises, Inc.)], a leading ...
... firm represents Pickerington man who contracted E. coli from ground beef ... ... (Lexis Nexis) July 25, 2008 -- http://www.donaheyohioinjurylawyers.com [The Donahey ... central Ohio, has filed a product liability lawsuit in Franklin County ...
... Colo., July 24 An Arapahoe County District,Court ... likely,amount to more than $1 million in damages ... of Inverness-based Verex, Inc., a public,company, and a ... found that PR Pharmaceuticals and its President, Steven ...
... Pa., July 24 HTH Worldwide, a global ... will begin offering its,CityHealth(R) Profiles to Living Abroad.com ... fact-filled online guides to trusted,medical care in hundreds ... tools and destination-driven information for those living,overseas or ...
... the commonest cause of blindness in the western ... the immune system influence the risk of contracting ... working in co-operation with researchers from Gttingen, Regensburg ... time, demonstrated that in cases of senile blindness ...
... sports,chiropractor, Dr. Camille Reagan to serve as a member ... Beijing. Dr. Reagan has extensive,experience in the international sports ... 2007 Pan American Games in Rio de Janeiro., ... an international sports,platform," said Dr. Reagan. "The athletes believe ...
Cached Medicine News:Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Jury Award to Englewood Company to Total More Than $1 Million for Breach of Fiduciary Duties in Shareholder Class Action Case 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:Hyperactive immune resistance brings blindness in old age 2Health News:Colombia Appoints Dallas Chiropractor to Olympic Team 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: